P-67 FREQUENCY OF MASLD IN INFLAMMATORY BOWEL DISEASE

Abstract

Conflict of interest: No Introduction and Objectives: Hepatic involvement as an extraintestinal manifestation of inflammatory bowel disease (IBD) has been widely described; however, there is limited information on the presence of non-alcoholic steatosis and hepatic fibrosis, as well as the recent definition of metabolic dysfunction-associated steatotic liver disease (MASLD). The aim of our study is to describe the frequency of non-alcoholic hepatic fibrosis and steatosis, as well as MASLD, and to describe the associated factors for these conditions. Patients / Materials and Methods: This is a cross-sectional and analytical study. Patients diagnosed with IBD were included, and transient hepatic elastography (THE) with iLivTouchFT100® /UAP was performed to obtain values of steatosis and hepatic fibrosis. Additionally, the presence of metabolic syndrome criteria was evaluated to diagnose MASLD. Demographic and clinical variables of the disease were recorded. For the statistical analysis, R Commander software and R Studio Desktop application were used. Results and Discussion: A total of 136 patients diagnosed with IBD were included, of which 80 (58.82%) were women and 56 (41.18%) were men. The mean age was 44.83 years (SD ±15.78). Regarding the type of IBD, 106 (77.9%) patients were diagnosed with UC, while CD was diagnosed in 30 (22.1%) patients; the majority, 90 participants (66.18%), presented some degree of hepatic steatosis, with mild being the most common in 34 patients (25%). Regarding fibrosis, 33 (24.26%) patients presented some degree of fibrosis. 76 (55.8%) patients were diagnosed with MASLD, while 14 (10.29%) patients with hepatic steatosis did not meet any criteria for metabolic syndrome. No significant differences were observed regarding disease activity, but differences were seen in nutritional variables such as BMI, weight, and waist circumference. Conclusions: In patients with IBD, the presence of non-alcoholic hepatic steatosis is significant, with 66.18% (n=90) of patients showing some degree of steatosis. More than half of the patients [n=76 (55.8%)] met the criteria for MASLD.